Towards new broader spectrum pneumococcal vaccines: The future of Pneumococcal disease prevention

Vaccines

Volumn 2, Issue 1, 2014, Pages 112-128

  Lee, Lucia H ^a   Gu, Xin Xing ^b   Nahm, Moon H ^c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Epidemiology; Pneumococcal protein; Serotype; Streptococcus pneumoniae; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; PROTEIN BASED PNEUMOCOCCAL VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

HUMAN; IMMUNIZATION; INCIDENCE; NONHUMAN; PNEUMOCOCCAL INFECTION; POLYMERASE CHAIN REACTION; POSTMARKETING SURVEILLANCE; REVIEW; SEROTYPE; SEROTYPE 19A; SEROTYPE 22F; SEROTYPE 6A; SEROTYPE 6C;

EID: 85019400400     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2010112     Document Type: Review

References (66)

1. McIntosh, E.D.; Reinert, R.R. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev. Vaccines 2011, 10, 109-129.
2. Munoz-Almagro, C.; Jordan, I.; Gene, A.; Latorre, C.; Garcia-Garcia, J.J.; Pallares, R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 2008, 46, 174-182.
3. Kaplan, S.L.; Mason, E.O., Jr.; Wald, E.R.; Schutze, G.E.; Bradley, J.S.; Tan, T.Q.; Hoffman, J.A.; Givner, L.B.; Yogev, R.; Barson, W.J. et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004, 113, 443-449.
4. Weil-Olivier, C.; van der Linden, M.; de Schutter, I.; Dagan, R.; Mantovani, L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. BMC Infect. Dis. 2012, 12, e207.
5. Williams, S.R.; Mernagh, P.J.; Lee, M.H.; Tan, J.T. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med. J. Aust. 2011, 194, 116-120.
6. Pilishvili, T.; Lexau, C.; Farley, M.M.; Hadler, J.; Harrison, L.H.; Bennett, N.M.; Reingold, A.; Thomas, A.; Schaffner, W.; Craig, A.S. et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 2010, 201, 32-41.
7. Johnson, H.L.; Deloria-Knoll, M.; Levine, O.S.; Stoszek, S.K.; Freimanis Hance, L.; Reithinger, R.; Muenz, L.R.; O'Brien, K.L. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The pneumococcal global serotype project. PLoS Med. 2010, 7, e1000348. doi:10.1371/journal.pmed.1000348.
8. Moore, M.R.; Gertz, R.E., Jr.; Woodbury, R.L.; Barkocy-Gallagher, G.A.; Schaffner, W.; Lexau, C.; Gershman, K.; Reingold, A.; Farley, M.; Harrison, L.H. et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 2008, 197, 1016-1027.
9. Pai, R.; Moore, M.R.; Pilishvili, T.; Gertz, R.E.; Whitney, C.G.; Beall, B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 2005, 192, 1988-1995.
10. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly. Rep. 2010, 59, 258-261.
11. Choi, E.H.; Kim, S.H.; Eun, B.W.; Kim, S.J.; Kim, N.H.; Lee, J.; Lee, H.J. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 2008, 14, 275-281.
12. Van, E.T.; Moore, M.R.; Fierens, F.; Whitney, C.G.; White, L.; Pelton, S.I.; Hausdorff, W.P. A dynamic model of pneumococcal infection in the United States: Implications for prevention through vaccination. Vaccine 2010, 28, 3650-3660.
13. Black, S. The volatile nature of pneumococcal serotype epidemiology: Potential for misinterpretation. Pediatr. Infect. Dis. J. 2010, 29, 301-303.
14. Fitzwater, S.P.; Chandran, A.; Santosham, M.; Johnson, H.L. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 2012, 31, 501-508.
15. Miller, E.; Andrews, N.J.; Waight, P.A.; Slack, M.P.; George, R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: An observational cohort study. Lancet Infect. Dis. 2011, 11, 760-768.
16. Park, I.H.; Pritchard, D.G.; Cartee, R.; Brandao, A.; Brandileone, M.C.; Nahm, M.H. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J. Clin. Microbiol. 2007, 45, 1225-1233.
17. Hiller, N.L.; Janto, B.; Hogg, J.S.; Boissy, R.; Yu, S.; Powell, E.; Keefe, R.; Ehrlich, N.E.; Shen, K.; Hayes, J. et al. Comparative genomic analyses of seventeen Streptococcus pneumoniae strains: Insights into the pneumococcal supragenome. J. Bacteriol. 2007, 189, 8186-8195.
18. McEllistrem, M.C.; Nahm, M.H. Novel pneumococcal serotypes 6C and 6D: Anomaly or harbinger. Clin. Infect. Dis. 2012, 55, 1379-1386.
19. Rolo, D.; Fenoll, A.; Fontanals, D.; Larrosa, N.; Giménez, M.; Grau, I.; Pallarés, R.; Liñares, J.; Ardanuy, C.; Serotype 5 Study Group. Serotype 5 pneumococci causing invasive pneumococcal disease outbreaks in Barcelona, Spain (1997 to 2011). J. Clin. Microbiol. 2013, 51, 3585-3590.
20. Van der Linden, M.; Winkel, N.; Kuntzel, S.; Farkas, A.; Perniciaro, S.R.; Reinert, R.R.; Imöhl, M. Epidemiology of Streptococcus pneumoniae serogroup 6 isolates from IPD in children and adults in Germany. PLoS One 2013, 8, e60848.
21. Cooper, D.; Yu, X.; Sidhu, M.; Nahm, M.H.; Fernsten, P.; Jansen, K.U. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011, 29, 7207-7211.
22. Oliver, M.B.; Jones, C.; Larson, T.R.; Calix, J.J.; Zartler, E.R.; Yother, J.; Nahm, M.H. Streptococcus pneumoniae serotype 11D has a bispecific glycosyltransferase and expresses two different capsular polysaccharide repeating units. J. Biol. Chem. 2013, 288, 21945-21954.
23. Camilli, R.; Bonnal, R.J.; del, G.M.; Iacono, M.; Corti, G.; Rizzi, E.; Marchetti, M.; Mulas, L.; Iannelli, F.; Superti, F. et al. Complete genome sequence of a serotype 11A, ST62 Streptococcus pneumoniae invasive isolate. BMC Microbiol. 2011, 11, e25.
24. European Centre for Disease Prevention and Control. Surveillance of Invasive Pneumococcal Disease in Europe; Stockholm, Sweden, 2010.
25. Lee, H.; Cha, J.H.; Nahm, M.H.; Burton, R.L.; Kim, K.H. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children. BMC Infect. Dis. 2013, 13, e474.
26. Feikin, D.R.; Kagucia, E.W.; Loo, J.D.; Link-Gelles, R.; Puhan, M.A.; Cherian, T.; Levine, O.S.; Whitney, C.G.; O'Brien, K.L.; Moore, M.R. et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: A pooled analysis of multiple surveillance sites. PLoS Med. 2013, 10, e1001517.
27. Antonio, M.; Dada-Adegbola, H.; Biney, E.; Awine, T.; O'Callaghan, J.; Pfluger, V.; Enwere, G.; Okoko, B.; Oluwalana, C.; Vaughan, A. et al. Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. BMC Infect. Dis. 2008, 8, e81.
28. Antonio, M.; Hakeem, I.; Awine, T.; Secka, O.; Sankareh, K.; Nsekpong, D.; Lahai, G.; Akisanya, A.; Egere, U.; Enwere, G. et al. Seasonality and outbreak of a predominant Streptococcus pneumoniae serotype 1 clone from The Gambia: Expansion of ST217 hypervirulent clonal complex in West Africa. BMC Microbiol. 2008, 8, e198.
29. Klugman, K.P.; Madhi, S.A.; Huebner, R.E.; Kohberger, R.; Mbelle, N.; Pierce, N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 2003, 349, 1341-1348.
30. Pan American Health Organization (PAHO). System Network Monitoring Responsible Agents of Bacterial Meningitis and Pneumonia. In SIREVA II Regional Reports; PAHO: Washington, DC, USA, 2013.
31. Fletcher, M.; Leeming, J.; Cartwright, K.; Finn, A. Childhood empyema: Limited potential impact of 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 2006, 25, 559-560.
32. Byington, C.L.; Hulten, K.G.; Ampofo, K.; Sheng, X.; Pavia, A.T.; Blaschke, A.J.; Pettigrew, M.; Korgenski, K.; Daly, J.; Mason, E.O. et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J. Clin. Microbiol. 2010, 48, 520-525.
33. Tan, T.Q.; Mason, E.O., Jr.; Wald, E.R.; Barson, W.J.; Schutze, G.E.; Bradley, J.S.; Givner, L.B.; Yogev, R.; Kim, K.S.; Kaplan, S.L. et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics 2002, 110, 1-6.
34. Shen, C.F.; Wang, S.M.; Lee, K.H.; Ho, T.S.; Liu, C.C. Childhood invasive pneumococcal disease caused by non-7-valent pneumococcal vaccine (PCV7) serotypes under partial immunization in Taiwan. J. Formos. Med. Assoc. 2013, 112, 561-568.
35. Resti, M.; Moriondo, M.; Cortimiglia, M.; Indolfi, G.; Canessa, C.; Becciolini, L.; Bartolini, E.; de Benedictis, F.M.; de Martino, M.; Azzari, C. et al. Community-acquired bacteremic pneumococcal pneumonia in children: Diagnosis and serotyping by real-time polymerase chain reaction using blood samples. Clin. Infect. Dis. 2010, 51, 1042-1049.
36. Obando, I.; Camacho-Lovillo, M.S.; Porras, A.; Gandía-González, M.A.; Molinos, A.; Vazquez-Barba, I.; Morillo-Gutierrez, B.; Neth, O.W.; Tarrago, D. Sustained high prevalence of pneumococcal serotype 1 in paediatric parapneumonic empyema in southern Spain from 2005 to 2009. Clin. Microbiol. Infect. 2012, 18, 763-768.
37. Isaacman, D.J.; McIntosh, E.D.; Reinert, R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: Impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int. J. Infect. Dis. 2010, 14, e197-e209.
38. Gladstone, R.A.; Jefferies, J.M.; Faust, S.N.; Clarke, S.C. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Rev. Vaccines 2012, 11, 889-902.
39. Pittet, L.F.; Posfay-Barbe, K.M. Pneumococcal vaccines for children: A global public health priority. Clin. Microbiol. Infect. 2012, 18, 25-36.
40. Van der Linden, M.; von Kries, R.; Imohl, M. Effects of immunization with higher valent pneumococcal conjugate vaccines in German children on numbers of reported IPD cases (1997-2012). In Proceedings of the 30th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Thessaloniki, Greece, 8-12 May 2012.
41. Ladhani, S.N.; Slack, M.P.; Andrews, N.J.; Waight, P.A.; Borrow, R.; Miller, E. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg. Infect. Dis. 2013, 19, 61-68.
42. Health Protection Agency. United Kingdom: Pneumococcal Disease. Avialiable online: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalData (accessed on 26 August 2013).
43. Andrews, N.; Kaye, P.; Slack, M.; George, R.; Miller, E. Effectiveness of the 13 valent pneumococcal conjugate vaccine against IPD in England and Wales. In Proceedings of the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Iguacu Falls, Brazil, 11-15 March 2012.
44. Moore, M.; Link-Gelles, R.; Farley, M.; Schaffner, M.; Thomas, A.; Reingold, A.; Harrison, L.; Lexau, C.; Zansky, S.; Petit, S. et al. Impact of 13-valent pneumococal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), U.S., 2010-2011. In Proceedings of the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Iguacu Falls, Brazil, 11-15 March 2012.
45. Gertz, R.E., Jr.; Li, Z.; Pimenta, F.C.; Jackson, D.; Juni, B.A.; Lynfield, R.; Jorgensen, J.H.; Carvalho Mda, G.; Beall, B.W.; Active Bacterial Core Surveillance Team. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J. Infect. Dis. 2010, 201, 770-775.
46. Le, C.F.; Palanisamy, N.K.; Mohd Yusof, M.Y.; Sekaran, S.D. Capsular serotype and antibiotic resistance of Streptococcus pneumoniae isolates in Malaysia. PLoS One 2011, 6, e19547.
47. Adam, H.J.; Karlowsky, J.A.; Nichol, K.A.; Gilmour, M.W.; Hoban, D.J.; Embree, J.; Zhanel, G.G. Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine. Microb. Drug Resist. 2012, 18, 176-182.
48. Hanage, W.P.; Bishop, C.J.; Huang, S.S.; Stevenson, A.E.; Pelton, S.I.; Lipsitch, M.; Finkelstein, J.A. Carried pneumococci in Massachusetts children: The contribution of clonal expansion and serotype switching. Pediatr. Infect. Dis. J. 2011, 30, 302-308.
49. Lehmann, D.; Willis, J.; Moore, H.C.; Giele, C.; Murphy, D.; Keil, A.D.; Harrison, C.; Bayley, K.; Watson, M.; Richmond, P. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin. Infect. Dis. 2010, 50, 1477-1486.
50. Johnson, D.R.; D'Onise, K.; Holland, R.A.; Raupach, J.C.; Koehler, A.P. Pneumococcal disease in South Australia: Vaccine success but no time for complacency. Vaccine 2012, 30, 2206-2211.
51. Kaplan, S.L.; Barson, W.J.; Lin, P.L.; Romero, J.R.; Bradley, J.S.; Tan, T.Q.; Hoffman, J.A.; Givner, L.B.; Mason, E.O., Jr. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 2013, 32, 203-207.
52. Skinner, J.M.; Indrawati, L.; Cannon, J.; Blue, J.; Winters, M.; Macnair, J.; Pujar, N.; Manger, W.; Zhang, Y.; Antonello, J. et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011, 29, 8870-8876.
53. Bologa, M.; Kamtchoua, T.; Hopfer, R.; Neveu, D.; Hu, B.; Sheng, X.; Corde, N.; Pouzet, C.; Zimmermann, G.; Gurunathan, S. Safety and immunogenicity of pneumococcal protein vaccine candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine 2012, 30, 7461-7468.
54. Frey, S.E.; Lottenbach, K.R.; Hill, H.; Blevins, T.P.; Yu, Y.; Zhang, Y.; Brenneman, K.E.; Kelly-Aehle, S.M.; McDonald, C.; Jansen, A. et al. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. Vaccine 2013, 31, 4874-4880.
55. Kamtchoua, T.; Bologa, M.; Hopfer, R.; Neveu, D.; Hu, B.; Sheng, X.; Corde, N.; Pouzet, C.; Zimmermann, G.; Gurunathan, S. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine 2013, 31, 327-333.
56. Pneumococcal protein vaccine safety and immunogencity trial (PPR02). Available online: http://clinicaltrials.gov/show/NCT01764126 (accessed on 18 January 2014).
57. Phase 1 safety trial of Streptococcus pneumoniae whole cell vaccine (SPWCV) + aluminum in healthy adults. Available online: http://clinicaltrials.gov/show/NCT01537185 (accessed on 18 January 2014).
58. Recombinant attenuated Salmonella typhi vaccine vectors producing Streptococcus pneumoniae PspA. Available online: http://clinicaltrials.gov/show/NCT01033409 (accessed on 18 January 2014).
59. Briles, D.E.; Hollingshead, S.K.; King, J.; Swift, A.; Braun, P.A.; Park, M.K.; Ferguson, L.M.; Nahm, M.H.; Nabors, G.S. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 2000, 182, 1694-1701.
60. Plumptre, C.D.; Ogunniyi, A.D.; Paton, J.C. Polyhistidine triad proteins of pathogenic streptococci. Trends Microbiol. 2012, 20, 485-493.
61. Godfroid, F.; Hermand, P.; Verlant, V.; Denoel, P.; Poolman, J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect. Immun. 2011, 79, 238-245.
62. Briles, D.E.; Hollingshead, S.K.; Paton, J.C.; Ades, E.W.; Novak, L.; van Ginkel, F.W.; Benjamin, Jr W.H. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J. Infect. Dis. 2003, 188, 339-348.
63. Denoel, P.; Godfroid, F.; Hermand, P.; Verlantm, V.; Poolman, J. Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides. Vaccine 2011, 29, 6451-6453.
64. Prymula, R.; Pazdiora, P.; Traskine, M.; Ruggeberg, J.; Borys, D. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins given to Czech toddlers. In Proceedings of the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Iguacu Falls, Brazil, 11-15 March 2012.
65. Lu, Y.J.; Leite, L.; Goncalves, V.M.; de Oliveira Dias, W.; Liberman, C.; Fratelli, F.; Alderson, M.; Tate, A.; Maisonneuve, J.F.; Robertson, G. et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010, 28, 7468-7475.
66. Malley, R.; Morse, S.C.; Leite, L.C.; Areas, A.P.; Ho, P.L.; Kubrusly, F.S.; Almeida, I.C.; Anderson, P. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect. Immun. 2004, 72, 4290-4292.